Ven­rock stocks up on $450M Fund 8 as it pre­pares a new string of biotech deals

The ven­ture part­ners at Ven­rock have an ap­petite for high-risk biotechs look­ing to break new ground. Now they have a new $450 mil­lion fund to sat­is­fy them­selves with a steady di­et of new deals ahead.

Bryan Roberts, a part­ner spe­cial­iz­ing in health­care who was in on Re­cep­tos ear­ly on — well be­fore Cel­gene ac­quired it for $7.2 bil­lion — used a blog post on the VC’s site to an­nounce the new fund, Ven­rock’s 8th. He wrote:

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA